• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . SARS-CoV-2 Antibody Levels and Infections in Multiple Vaccinated Employees Over Time

tetano

Editor, Senior Moderator
J Med Virol


. 2025 Oct;97(10):e70628.
doi: 10.1002/jmv.70628. SARS-CoV-2 Antibody Levels and Infections in Multiple Vaccinated Employees Over Time

Ingrid Sander[SUP] 1 [/SUP], Sabine Kespohl[SUP] 1 [/SUP], Alexandra Beine[SUP] 1 [/SUP], Kerstin Belting[SUP] 1 [/SUP], Jürgen Bünger[SUP] 1 [/SUP], Simon Weidhaas[SUP] 1 [/SUP], Ingolf Hosbach[SUP] 1 [/SUP], Christian Eisenhawer[SUP] 1 [/SUP], Jan Gleichenhagen[SUP] 1 [/SUP], Philipp Göcke[SUP] 2 [/SUP], Thomas Brüning[SUP] 1 [/SUP], Monika Raulf[SUP] 1 [/SUP]



Affiliations
Abstract

This prospective cohort study aimed to monitor the humoral immune response to SARS-CoV-2 proteins over 3 years in relation to repeated vaccination or infection. Quantitative immunoassays traceable to international IgG units were used to measure and compare IgG levels against Wuhan type and Omicron spike-S1 and nucleocapsid proteins over 3 years. In addition, the Euroimmun-N-test was used to determine positive IgG values against the nucleocapsid. A total of 1223 serum samples from 126 participants without evidence of COVID-19 at enrollment were analyzed and used to calculate antibody half-lives following vaccination or infection, as reported by the questionnaire. Antibody levels and half-life against both variants of the spike S1 protein increased significantly with each additional vaccination or after infection. IgG against the Wuhan type was, on average, three times higher than against the Omicron variant. The half-lives of antibodies against the Wuhan type after the second and third vaccinations and after infection were significantly longer than those of IgG against the Omicron variant. Two-thirds of the cohort reported COVID-19 infection, detected with a sensitivity of 70% by the quantitative nucleocapsid IgG assay and 83% by the Euroimmun-N-test. The level of anti-nucleocapsid-IgG after infection in the vaccinated cohort was significantly lower than anti-S1-IgG and also lower than in unvaccinated infected persons. Despite repeated vaccinations and progressively increasing IgG antibody levels targeting the spike protein, most of the cohort reported breakthrough infections, possibly due to the lower concentration and reduced half-life of antibodies against the Omicron variant.

Keywords: Omicron; SARS‐CoV‐2 vaccination; antibody levels; half‐life of specific IgG; nucleocapsid; spike.

 
Back
Top Bottom